Gene therapy for Duchenne muscular dystrophy.

Area of Science:

• Neuromuscular Disorders
• Genetics
• Gene Therapy

Background:

• Duchenne muscular dystrophy (DMD) is a severe X-linked disorder causing progressive muscle degeneration due to DMD gene variants.
• Adeno-associated virus (AAV)-mediated micro-dystrophin delivery represents a key advancement in DMD gene therapy.
• Delandistrogene moxeparvovec, the first FDA-approved gene therapy for DMD, shows early promise but requires further evaluation of long-term outcomes.

Purpose of the Study:

• To review the current landscape of gene therapy for DMD.
• To highlight progress, challenges, and future directions in DMD gene therapy.
• To inform the safe and effective clinical application of gene therapies for DMD.

Main Methods:

• Review of current gene therapy approaches for DMD, including micro-dystrophin replacement.
• Exploration of novel strategies like endogenous dystrophin upregulation and exon skipping.
• Discussion of challenges such as immune-mediated toxicities and vector limitations.

Main Results:

• AAV-mediated micro-dystrophin delivery has shown transgene expression and potential functional benefits in early trials.
• Immune toxicities (myositis, myocarditis, liver injury) are significant challenges requiring management.
• Various strategies are being developed to overcome vector limitations and improve treatment eligibility.

Conclusions:

• Gene therapy offers new avenues for DMD treatment, with delandistrogene moxeparvovec as a landmark approval.
• Addressing safety concerns, optimizing delivery, and expanding access are critical for widespread clinical use.
• Continued research into novel vectors and therapeutic strategies is essential for advancing DMD care.